Scancell Share Discussion Threads

[bermudashorts] 02/10/2018 13:26

Tosh,

That's a bit of a leap isn't it? Not sure how you can draw any conclusions from the fact that Roche have signed a tiny (pocket money by their standards) deal with GO.

[tosh123] 02/10/2018 13:14

Good find Gooosed.
Seems a shame though because i thought that RG had inferred that we were relatively close to Roche, and that they would be our preferred partner ( i could be wrong though ).
If my memory serves me right and im correct with the above, it would suggest that they have looked at the data room, and decided to deal elsewhere !

[drdobson1] 01/10/2018 19:01

Goosey who is right on the argument on MFFF regarding whether this new development is a new platform or simply a modification for Moditope.
In the blue corner you have well respected science poster Barmooda Shorties and in the PLUM coloured corner you have Failed Prof baNANA a known liar and EGOtist with a proven track record of stealing other scientists CONtributions and of Failed predictions
I know who my money is on and it ain’t PLUM DUFF

[gooosed] 01/10/2018 17:43

Moditope evolving - will be interesting to see what CRUK GC adds if project Blueprint is selected.

In my opinion Nextlink there's too much under one platform for Scancell to develop on their own. If the current research collaboration with BioNTech produces interest (Q22019) then Scancell may well secure the chance to see Lindy's work taken to the next level. A few more years - maybe, maybe not but good luck.

[nextlink] 01/10/2018 13:59

I keep a close eye just in case and sympathise with current investors.
Sold out a few years ago and at the time had the concern I might miss
a spectacular rise a few months later.
I would never say I would not buy in again, as the company has considerable
patented IP, which might or might not have considerable value at some point.
From my perspective there is little to tempt me, it feels as if I have a few
more years to consider investing, possibly at a much lower share price

[sarkasm] 01/10/2018 13:41

Back
Roche buys Tusk, plus cancer immunotherapy drug, for £62m

Roche buys Tusk, plus cancer immunotherapy drug, for £62m
Joy PersaudJoy Persaud
October 1, 2018

Roche has bought immuno-oncology biotech firm Tusk Therapeutics for an upfront payment of £62 million.

Tusk’s shareholders will receive the upfront cash payment, plus additional contingent payments of up to £521 million, if and when certain milestones are achieved.

Tusk, which is based in Stevenage, has developed a first-in-class antibody, CD25, for the depletion of regulatory T-cells (TRegs), which suppress the body’s immune reaction to cancer cells.

This novel antibody enables the body’s other immune cells to fight tumours while leaving healthy tissue unharmed. Clinical trials are expected to start next year.

Luc Dochez, CEO of Tusk Therapeutics, said: “We are delighted that Roche will further develop this novel antibody and drive the development ahead.

“The remaining portfolio of our immune-oncology targets will be further developed by Black Belt Therapeutics, a newly formed company spun out of Tusk Therapeutics.”

Droia Oncology Ventures, Tusk’s majority shareholder, founded the company in 2014. Droia is a specialist investor, which focuses on fighting cancer.

It invests in promising new cancer therapies and accelerates their progress by actively supporting young drug development companies to achieve clinical proof of concept with their lead programmes. The deal will expand Roche’s oncology pipeline.

Also, Roche today announced a new collaboration with Novo Nordisk, which specialises in the treatment and management of diabetes and obesity.

The plan is to integrate insulin dosage information from Novo Nordisk’s connected pen technology into Roche’s open ecosystem, whereby it will communicate with its digital diabetes management solutions including mySugr, which allows people to monitor their glucose levels.

Marcel Gmuender, global head of Roche Diabetes Care, said: “The integration of insulin pen data in our digital health solutions such as mySugr will make it much easier for people with diabetes and their caregivers to track the effect of insulin on blood glucose levels.

“This enables more efficient and targeted decision support, as they can act on near real-time insights to optimise the personalised diabetes management, thereby reducing the risk of costly secondary complications and contributing to improved therapy outcomes and better quality of life.”

Anders Toft, corporate vice president of commercial innovation at Novo Nordisk, echoed this, adding: “Digital health solutions like mySugr are already helping thousands of patients. By integrating Novo Nordisk connected technology with mySugr, we can further ease the day-to-day burden of disease management and provide data-based insights to improve the dialogue between patients and caregivers.”





Don't miss your daily pharmaphorum news

[torquayfan] 01/10/2018 12:39

10acious. Thanks. On the other side, it has been noted that James P Allison is listed as an Investigator at M D Anderson re. the coming SCIB1 Combo trial. Interesting.

James P Allison's name is on every news screen in the World tonight - let's hope he gives Scancell a mention sometime ! GLA

[drdobson1] 01/10/2018 12:12

Thanks Goosey.Great input.
Meanwhile of MFFF.PLUM gets more desperate as he suffers bigger losses claiming 4th Plaform nailed on for SCLP.
When this drops lower he will claim Platform 10.Well I ruddy well wish he go to Platform 10and get the first train out to INANACOmbe Pier.
Will fall in sea but he is used to being underwater with the PLANKton ha ha ha ha

[terror] 29/9/2018 17:05

TurkeyFan needs to get back to more 'self pleasure' as he has clearly lost the plot.

[panama7] 29/9/2018 16:30

Lozan, excellent post and it would appear more Investors are now willing to share those views of the BOD.

[the real lozan] 29/9/2018 13:04

Little things mean a LOT -
At a time { or any time for that matter} when SO MUCH depends on this company 'attracting' VITAL 'funds', one might assume it 'politic' to present an image of 'careful use of any potential funds' ???
There seems to be a 'tendency' to provide 'hints' that this might not appear to be the case with SCLP BoD actions.
When *WE ALL* see 'personal rewards' somewhat 'Out-of-BALANCE' to 'actual progress' and other examples =
For instance, the recent 'extravagance' of possibly 4 RNSs... Where 1 well-formed RNS would have 'sufficed' ???
Does this ' present an image of 'careful use of any potential funds' ???
Or
Might these 'examples' send-out-a-message... that = *It matters NOT to BoD, the shareholders will PAY for it*
.
Little things SAY a LOT
The S P SAYS a LOT MORE

[panama7] 29/9/2018 10:26

I imagine the BOD have delayed the announcement of the AGM so that they have time to relocate that Rabbit that they need to pull out of the hat.

[gooosed] 29/9/2018 10:26

torquayfan - indeed nothing much has changed - for the better.

The SCIB1 IND after months & months remains unresolved.

Modi-1 trial delayed.

Chiplin promised regular updates - radio silence.


Positive news might have made the ridiculous salary increases easier to swallow.

A UK micro cap Biotech includes future tax credits in their budgets for development of IP and then awards themselves ridiculous salary increases.

Awarded by US based members of the remuneration committee that have presided over a failed funding strategy.

One item of intrigue - who now Co leads Project Blueprint & why was that new info dropped into the Final results.

[panama7] 29/9/2018 10:21

Goosed, excellent recap, it's good to see even respected Investors like yourself questioning the BOD and the ever failing timelines.

[torquayfan] 29/9/2018 10:12

Good that you had a laugh Ruck - you certainly needed cheering up !

Inan simply points out that market 'quirks' are not important because funds are in place to maintain the current areas of exciting progress. Of course, in the longer term the market will not be wrong but aren't you living in hopes too ? Or why would you be here ?

BTW - just English - 'More than' permanent does not exist.

Anyway - GLA and BFN

[drdobson1] 29/9/2018 09:16

Goosey.Yes huge ha ha and smacks of desperation as sheep Swallow trHYPE as Loz suggests.
baNANA thinks RHatton is silly at selling but as Loz says he has trousered £350 if he bought back.Would pay for PLUM to spend days playing the penny slot machines onINANACOmbe pier for months.Probably a better risk/reward play given his investment record.Guffaw.
We know how placements work the issue is at what price and what discount to current share price We can be certain the next placing will be st much less than 10p if lack of communication CONtinues.
He says there is much going on well obviously he sees things others cannot as they have not told us what is going on.
No IND yet only 3 years late,delays to Modi and CzrUzk deal
All jam tomorrow the only thing we know about is the INfksted salaries given to part timers.Wont take long for BOD to get through cash pile for their own lifestyles and as long as likes of PLUM are not brave enough to question their records then he will go further underwater